Project NK-001-2 (Q3679046)

From EU Knowledge Graph
Revision as of 14:45, 26 November 2021 by DG Regio (talk | contribs) (‎Changed label, description and/or aliases in de: translated_label)
Jump to navigation Jump to search
Project Q3679046 in France
Language Label Description Also known as
English
Project NK-001-2
Project Q3679046 in France

    Statements

    0 references
    421,650.09 Euro
    0 references
    648,692.45 Euro
    0 references
    65.0 percent
    0 references
    4 January 2016
    0 references
    20 November 2021
    0 references
    Centre Hospitalier Régional Universitaire de Montpellier
    0 references
    0 references
    Le projet a pour but de développer un nouveau médicament pour le traitement du cancer basé sur l’efficacité des mécanismes naturels anti-leucémiques des cellules NK (Natural Killers). L'utilisation des cellules NK constitue aujourd'hui une alternative majeure pour le traitement de pathologies tumorales. Le projet explore également les applications des cellules NK avec les Mab (anticorps monoclonaux). (French)
    0 references
    The project aims to develop a new drug for the treatment of cancer based on the effectiveness of natural anti-leukemic mechanisms of NK cells (Natural Killers). The use of NK cells is now a major alternative for the treatment of tumour pathologies. The project also explores NK cell applications with Mab (monoclonal antibodies). (English)
    18 November 2021
    0 references

    Identifiers

    LR0002193
    0 references